US FDA authorises phase 1 trial of ImmunityBio’s COVID-19 vaccine candidate hAd5
Ongoing development proceeding for oral, inhalational and intranasal administration of hAd5
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.